Investigator Initiated Treatment Clinical Trials for Cancer
APPLICATIONS DUE July 13, 2020
Priority will be given to trials with the following features, though exceptions may be accepted: Any treatment area of cancer including, but not limited to, treatment trials of advanced or early stage disease, or in supportive care. Trials may evaluate repurposing of drugs or combinations of drugs already in clinical use but study novel applications or in understudied populations.
Priority will be given to trials with the following features though exceptions may be accepted:
- Any treatment area of cancer including but not limited to treatment trials of advanced or early stage disease, or in supportive care. Trials may evaluate repurposing of drugs or combinations of drugs already in clinical use but study novel applications or in understudied populations.
- Trials must be considered therapeutic and must register in clinicaltrials.gov. A key feature of successful applications is that accruals will count towards our treatment enrollment targets
- Full accrual should be feasible within 12-24 months from start of trial. Ideally, outcomes should be publishable soon after final accrual.
- Procedures and drugs are billable to insurance and considered standard of care.
- If drugs are not commercially available for the indication studied, they must be supplied by the manufacturer. Budget will not be sufficient to cover high-cost drugs.
- Funds will generally be used to cover start-up and study personnel time but may also be used for specimen collection (including research biopsy) and processing.
- Includes a translational outcome (e.g., tissue, blood, DNA/RNA) including collaboration of at least one UICC co-PI (laboratory or non-laboratory). Results should be leverage able for future grant applications or additional trials
The application should include the following information:
- 1-page PDF describing the project and include rationale, hypothesis, simple trial details (patient population, number needed to recruit), anticipated outcomes and brief biostatistical plan. Brevity and clarity are appreciated.
- A second optional page can be included with figures or any references needed to better understand the proposal.
- No budget is needed at this time.
All applications will be reviewed and in person verbal feedback will be provided. An opportunity for applicants to clarify aspects of their applications will be provided. 2-3 trials will be funded depending on scope and budget of projects deemed most worthy.
Applications will be reviewed on a rolling basis starting on June 22nd and selected projects will be funded immediately upon approval of the PRC and IRB until funds are exhausted. Applications submitted after July 13th, 2020 will not be considered for funding.
Please direct questions to Darlene Kitterman at email@example.com.